LDLR and familial hyperaldosteronism: It has been estimated that a 1 mmol/l reduction in plasma LDL cholesterol reduces CAD risk by 20%18 so the reduction seen in the LV-LDLR and AAV9-LDLR groups could translate into clinical benefit in homozygous FH patients.